BRIEF — Encouraging trial results for Daiichi anti-stroke therapy

Daiichi Sankyo's Lixiana (edoxaban) has announced positive results from the ENGAGE AF-TIMI 48 trial, with the drug reducing the likelihood of intercranial haemorrhage (ICH) among patients suffering from atrial fibrillation (AF).

AF sufferers in the trial were found to be 42% less likely to suffer spontaneous ICH and 62% less likely to experience traumatic ICH when taking the drug.

Paul Giugliano, co-author of the study, said: “Results from the sub-analysis of the ENGAGE AF-TIMI 48 trial suggest that edoxaban offers an advantage over warfarin in patients who need anticoagulation and are at risk of ICH, providing guidance and offering further assurance to physicians regarding its use."